Premature Ejaculatio*n Treatment Market Analysis 2024 -2033: Forecasted Market Size, Top Segments, And Largest Region | Pfizer Inc., Johnson & Johnson, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2191

The Business Research Company offers in-depth market insights through Premature Ejaculatio*n Treatment Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The premature ejaculatio*n treatment market size has grown strongly in recent years. It will grow from $3.53 billion in 2023 to $3.88 billion in 2024 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to increasing prevalence of premature ejaculatio*n, growing awareness and reduced stigma, physician and patient education, changing societal attitudes toward sexual health, expansion of telemedicine services, pharmaceutical industry initiatives..

The premature ejaculatio*n treatment market size is expected to see strong growth in the next few years. It will grow to $5.62 billion in 2028 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to continued focus on sexual health, individualized treatment approaches, global efforts to address sexual dysfunction, online health platforms and apps, increased openness in healthcare discussions.. Major trends in the forecast period include rise in behavioral and psychosexual therapies, development of novel topical therapies, advancements in pharmacological treatments, integration of telemedicine and online platforms, focus on patient education and counseling, research on novel mechanisms of action..

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=13518&type=smp

Market Segmentation:
The main types of premature ejaculatio*n treatments are antidepressants (SSRIs), phosphodiesterase-5 inhibitors, topical anesthetics, analgesics, and others. Selective serotonin reuptake inhibitors (SSRIs) refer to an antidepressant medication for depression. The various routes of administration are oral and topical, channeled through retail and direct-to-consumer. The various applications are hospitals, retail pharmacies, online pharmacies, and others.

Major Driver - Rising Prevalence Of Sexual Disorders Fuels Growth In The Premature Ejaculatio*n Treatment Market
The increasing prevalence of sexual disorders is expected to propel the growth of the premature ejaculatio*n treatment market going forward. Sexual disorder or dysfunction refers to the difficulty faced by both men and women during any phase of regular intimate activity. Premature ejaculatio*n is a sexual disorder where premature ejaculatio*n treatment involving medications or therapeutic approaches addresses and controls this condition. For instance, in November 2021, according to a survey of 2,000 UK adults conducted by Pharmacy Direct GB, a UK-based online pharmacy, around 48% of UK residents reported experiencing erectile dysfunction, representing about 16.5 million individuals. The National Health Service spent over $17,9 million (£13 million) for Erectile Dysfunction treatment prescriptions in 2021. Further, in July 2022, according to a survey of 1,000 men across the UK by Click2Pharmacy, a UK-based provider of local prescription treatment services, around 58.2% experienced erectile dysfunction in the UK and 3 in 4 men between the ages of 25 and 34 experience erectile dysfunction in 2022. Therefore, the increasing prevalence of sexual disorders is driving the growth of the premature ejaculatio*n treatment market.

Competitive Landscape:
Major companies operating in the premature ejaculatio*n treatment market report are Pfizer Inc., Johnson & Johnson, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, AstraZeneca PLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Menarini Group, Lupin Limited., Amneal Pharmaceuticals Inc., Mankind Pharma Ltd., Cipla Limited, Alembic Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., ANI Pharmaceuticals Inc., Sagent Pharmaceuticals Inc., Vivus Inc., Absorption Pharmaceuticals LLC, Innovus Pharmaceuticals Inc., Sunrise Pharmaceuticals Inc., Solco Healthcare US LLC, Apricus Biosciences Inc., Regent Pacific Group Limited, Endurance RP Ltd.

Get Access To The Full Market Report -
https://shorturl.at/joAY2

Top Trend - Innovative Delay Sprays Transforming The Premature Ejaculatio*n Treatment Market
Major companies operating in the premature ejaculatio*n treatment market are developing new solutions, such as delay sprays, to drive revenues in the market. Delay sprays, specifically prepared products applied to the peni*s before sexual activity to assist men last longer during sexual intercourse, work by momentarily dulling peni*s nerves, lowering peni*s sensitivity, and postponing ejaculatio*n. For instance, in August 2023, Maude, a US-based sexual wellness company, launched Stay, a delay spray explicitly designed to address premature ejaculatio*n. This product is infused with 10% lidocaine, a fast-evaporating local anesthetic that reduces sensitivity in the male genital region. Furthermore, Stay is compatible with both latex and polyisoprene condoms, as well as various lubricants and devices. It's vegan-friendly, fragrance-free, and free from sulfates, silicones, and parabens.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Premature Ejaculatio*n Treatment Market Characteristics
3. Premature Ejaculatio*n Treatment Market Trends And Strategies
4. Premature Ejaculatio*n Treatment Market - Macro Economic Scenario
5. Premature Ejaculatio*n Treatment Market Size And Growth
…..
27. Premature Ejaculatio*n Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.